Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
A novel mechanism—similar to how normal tissue stem cells respond to wounding—might explain why bladder cancer stem cells actively contribute to chemoresistance after multiple cycles of chemotherapy drug treatment. Targeting this “wound response” of cancer stem cells can...
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
In the largest series of its kind to date, researchers at Roswell Park Cancer Institute (RPCI) have shown that performing thoracoscopic pneumonectomy, removal of the entire lung through a minimally invasive endoscopic approach, at a high-volume center appears to be safe and may provide pain and...
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete survivorship care plans, lack of role clarity, and lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship...
Researchers at the University of California, San Diego, School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. Of note was the discovery that patients of Asian...
Robert S. Miller, MD, FACP, FASCO, Assistant Professor of Oncology and Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, has been named Medical Director of the Institute for Quality (iQ) of the American Society of Clinical Oncology (ASCO). ...
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy extended survival over systemic therapy alone in well-selected candidates with peritoneal hepatocellular carcinoma, according to the results of a small retrospective trial reported by Tabrizian et al in the Journal of...
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...
The 1964 Surgeon General’s Report on Smoking and Health started a culture change in the way Americans viewed tobacco and their health, and has saved countless million of lives. But the 1964 Report remained scientifically ambiguous on certain vital issues, such as the effect smoking had on the ...
Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...
Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified a gene that contributes to the development of several childhood cancers, in a study conducted in mouse models. If the findings prove to be applicable to humans, the research could...
The BRAF inhibitor vemurafenib (Zelboraf) is approved for treatment of BRAF-mutated metastatic melanoma. There are reports indicating that vemurafenib may be active in the treatment of intracranial neoplasms with BRAF mutations. As reported in the Journal of Clinical Oncology, Lee et al from...
Cancer research lost a pioneer on August 3, 2014, with the passing of Emmanuel Farber, MD, PhD, a renowned pathologist who made fundamental contributions to our understanding of chemical carcinogenesis. Dr. Farber’s studies in experimental pathology demonstrated that chemical carcinogens are...
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other...
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute. In a study reported in Nature, Spiegelman et al...
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study recently published in Nature Genetics. The research team, which included researchers at the Icahn School of Medicine at Mount Sinai, found that variations in the TANC1 gene are associated with...
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, preclinical study published in Nature Communications indicated. The finding by Watkins et al could ultimately lead to new ways to bring about the ...
Invasive breast cancers with skin involvement, regardless of size or lymph node involvement, are automatically classified as stage III locally advanced tumors, which suggests that they are a relatively serious form of cancer with poor survival. In a study published in the Journal of the American...
The effect of neoadjuvant chemoradiation therapy in early-stage esophageal cancer is not clear. In the phase III FFCD 9901 trial reported in the Journal of Clinical Oncology, Mariette et al found that neoadjuvant chemoradiation including fluorouracil (5-FU) and cisplatin did not improve R0...
In the German phase III CONKO-003 trial reported in the Journal of Clinical Oncology, Oettle et al found that second-line oxaliplatin, leucovorin, and fluorouracil (5-FU) significantly increased overall survival and time to progression vs leucovorin/5-FU in patients with advanced pancreatic cancer...
St. Jude Children’s Research Hospital announced the appointment of James R. Downing, MD, as its new CEO, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. He succeeds William E. Evans,...
In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to...
A study by researchers from Danbury Hospital Biomedical Research Institute in Connecticut has found that patients with ovarian cancer who relapse shortly after neoadjuvant chemotherapy to shrink their tumor prior to surgery have high levels of expression of HGF and c-Met proteins. The...
As reported in JAMA Ophthalmology, McCannel and colleagues identified three cases of subfoveal neurosensory retinal detachment among patients receiving MEK inhibitor therapy for metastatic cancer in clinical trials requiring ophthalmologic examination at their institution. In all cases, the toxic...
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
In a phase III trial (CA184-043) reported in The Lancet Oncology, Kwon et al assessed the effects of adding ipilimumab (Yervoy) after radiotherapy in patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy. The investigators found no improvement...
A new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient’s cancer has been developed by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health. The researchers demonstrated that the human immune...
A surgical method combining two techniques for removing precancerous polyps during colonoscopies can substantially reduce the recovery time and the length of hospital stays, which may translate into significant cost savings, according to research presented this week at Digestive Disease Week in...
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and frequent exercise are not only key to a healthy lifestyle, but a strategy to ...
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized three-dimensional (3D) MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy is working. The investigators said ...
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...
The members of the American Association for Cancer Research (AACR) have elected José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center in New York, as their President-Elect for 2014–2015. Dr. Baselga is an internationally recognized physician-scientist...
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research published in the Journal of Clinical Investigation by Koay et al, the scans also reflect how well chemotherapy will penetrate the tumor,...
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to a study by Chandwani et al published in the Journal of Clinical Oncology. While simple stretching activities counteracted fatigue, patients who participated in yoga exercises ...
A large population-based study by Landgren et al has found that African Americans are more likely to have a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor to the development of multiple myeloma, compared with whites or Hispanics. The study is published...
For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and...
New research is showing that sparing the contralateral submandibular gland during radiation therapy in the treatment of locally advanced head and neck cancer is technically feasible and safe even in advanced-stage, node-positive disease and base-of-tongue lesions. Limiting radiation to these major...
Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab (Yervoy), according to a study by Yuan et al published in Cancer Immunology Research....
When oncologists see a new patient, they should emphasize careful documentation of first- and second-degree cancer family history, according to new recommendations published by the American Society of Clinical Oncology. The recommendations are the first to focus on family history-taking...
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients. The study, published in...
In laboratory experiments conducted on human cell lines at the Johns Hopkins Sidney Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by acetaldehyde, a ...
The drug metformin, which is approved for the treatment of type 2 diabetes, has been tested in clinical trials as a tumor suppressor in different cancers due to its role in activating the AMPK signaling pathway. However, a new study by Liu et al published in Proceedings of the National Academy of...
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...